HNL Lab Medicine Earns Record 12 Reputation 800 Awards for Patient Experience Excellence
Reputation 800 Award HNL Lab Medicine Earns Reputation 800 Award ALLENTOWN, Pa., March 26, 2026 (GLOBE NEWSWIRE) -- HNL Lab...
Day: March 26, 2026
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026
Virtual Event will feature Key Opinion Leaders (KOLs) Richard DiPaolo, PhD, and Jonathan Kay, MD, FACP, MACR Cue Biopharma management and...
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026
Virtual Event will feature Key Opinion Leaders (KOLs) Richard DiPaolo, PhD, and Jonathan Kay, MD, FACP, MACR Cue Biopharma management and...
Geron Announces Appointment of New Members to its Board of Directors
Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companiesFOSTER CITY,...
Geron Announces Appointment of New Members to its Board of Directors
Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companiesFOSTER CITY,...
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
- Mr. McElheney brings more than 15 of years’ experience in corporate development and alliance management at biopharma companies. - ...
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
- Mr. McElheney brings more than 15 of years’ experience in corporate development and alliance management at biopharma companies. - ...
Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026
OAK RIDGE, TN, March 26, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...
Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026
OAK RIDGE, TN, March 26, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...
Firefly Confirms Public-Private Partnership with the Department of War
Firefly’s AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service...
Firefly Confirms Public-Private Partnership with the Department of War
Firefly’s AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service...
BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD
BURLINGTON, Mass. and JERUSALEM, March 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD
BURLINGTON, Mass. and JERUSALEM, March 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
-Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference...
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
-Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference...
Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007
At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral...
Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007
At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral...
Spectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate Update
TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company...
Avicanna Subsidiary SMGH Completes First Commercial Export to Australia
This marks the first commercial export of organic certified flower for SMGH The export represents the 21st market for SMGH and...
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
200µg Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical...